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Abbreviations used
Actb: Housekeeping gene b-actin
AD: Atopic dermatitis
CCL: Chemokine C-C motif ligand
CLA: Cutaneous lymphocyte antigen
CXCL: C-X-C motif chemokine ligand
DC: Dendritic cell
DLN: Draining lymph node
DSS: Dextran sulfate sodium salt
EB: Evans blue dye
FACS: Fluorescence-activated cell sorting
HD: Healthy donor
H&E: Hematoxylin and eosin
MLN: Mesenteric lymph node
OS: Omenn syndrome
OT: OVA transgenic mouse
OVA: Ovalbumin
PLN: Peripheral lymph nodes
Rag2R229Q: 129Sv/C57BL/6 knock-in Rag2R229Q/R229Q
TLR: Toll-like receptor
WT: Wild type
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Maintenance of skin homeostasis relies on the crosstalk among
epidermal keratinocytes, resident immune cells, and commensal
microbiota. Breaching of the cutaneous barrier and inadequate or
excessive immune response to microbial challenges potentially
lead to chronic inflammation and autoimmunity.1 A large number
of T cells normally populate the skin, providing immune surveil-
lance. In addition to this resident population, a subset of recircu-
lating memory T cells has been identified, contributing to
widespread immune protection of distal lymphoid and cutaneous
tissues.2,3 Migration of T cells into the skin requires ligands for
E- and P-selectin, among which an important role is played by
the P-selectin ligand CD162, also known as cutaneous lympho-
cyte antigen (CLA).4 Moreover, skin-homing T cells express the
chemokine receptors CCR4 and CCR10, whose ligands
—chemokine C-C motif ligands (CCL)17, CCL22, and CCL27
—are upregulated in the dermal vasculature and in epidermal ker-
atinocytes in many inflammatory conditions.5-7 Imprinting of
skin-homing properties in T cells critically depends on skin-
derived dendritic cells (DCs); T cells activated in skin-draining
peripheral lymph nodes (PLNs) express higher levels of selectin
ligands than those activated in mesenteric lymph nodes
(MLNs).5 Conversely, the gut-homing receptors a4b7 and
CCR9 are preferentially induced when T cells are activated in
MLN.8 Thus, in general, effector T cells trafficking to the skin
are devoid of gut-homingmolecules and gut-tropic cells do not ex-
press skin-homing molecules. Nonetheless, evidence of plasticity
in the homing phenotype has been accumulating in the context of
inflammation.9
Cutaneousmanifestations are common in patients with primary
immunodeficiency disease.10,11 Omenn syndrome (OS) is a se-
vere immunodeficiencymost often caused by hypomorphic muta-
tions in the RAG family, leading to generation of oligoclonal T
cells that expand in the periphery and infiltrate various organs,
particularly barrier tissues such as skin and gut.12 The most
distinctive clinical feature of OS is a generalized exfoliative er-
ythroderma with onset at neonatal age, associated with alopecia,
lymphadenopathy, hepatosplenomegaly, recurrent and severe in-
fections, and failure to thrive.12 Skin biopsies from patients
with OS reveal massive T-cell infiltration and an aberrant distribu-
tion of Langerhans cells, indicating that immune abnormalities
play an important role in the skin disease pathophysiology.13,14
Patients with OS also frequently suffer from chronic diarrhea,
and biopsies of the gastrointestinal tract reveal prominent T-cell
and eosinophil infiltrates in the lamina propria, villous flattening
in the small bowel, and cryptitis in the colon.15 A close associa-
tion between skin disease and microbiota (not limited to skin mi-
crobiota) has been demonstrated. For instance, atopic dermatitis
(AD) and rosacea are both linked to changes in the gut barrier
and intestinal microbiota.16 Reduced microbial diversity was re-
ported in infants with eczema.17,18 Furthermore, a link between
imbalances of the intestinal microbial communities and develop-
ment of skin psoriasis has been documented in mice andpatients.19 We have recently demonstrated that intestinal micro-
biota play a major role in the immune dysregulation of the
129Sv/C57BL/6 knock-in Rag2R229Q/R229Q (Rag2R229Q) mouse
model of OS, leading to the systemic dissemination of gut-
derived proinflammatory TH1/TH17 cells.
20 Whether such alter-
ations in gut homeostasis may also influence the cutaneous
manifestations of OS is not known.
Here, we provide evidence supporting a role for gut-skin axis in
the pathophysiology of OS. We found that compromised skin
barrier integrity in Rag2R229Q mice results in altered microbial
load and composition and dysregulated production of T cell–
recruiting chemokines by activated epithelial cells. Importantly,
intestinal inflammation and gut barrier leakage synergistically
support the activation of skin epithelial cells and the recruitment
of T cells to the skin. An increased proportion of circulating T
cells expressing skin-homing receptors and elevated plasma
levels of LPS and skin chemoattractants have been also docu-
mented in patients with OS, suggesting that mechanisms similar
to those observed in the mouse model may also operate to induce
skin inflammation in humans.METHODS
Human studies
Patient’s samples were collectedwith the informed consent of their parents,
according to protocol 18-I-0041 approved by the National Institutes of Health
institutional review board and protocols TIGET06 and TIGET09 approved by
the San Raffaele Scientific Institute ethics committee. Table E1 (in the Online
Repository available at www.jacionline.org) describes clinical, immunolog-
ical, and molecular features of 15 unrelated patients with OS. A cohort of
age-matched healthy donors (HDs), patients with acute graft-versus-host dis-
ease and patients with AD were also studied as controls. PBMCs from periph-
eral bloodwere purified on Ficoll gradient (Lympholyte cell separationmedia;
Cedarlane Laboratories, Burlington, Ontario, Canada).Mice
The Rag2R229Q mice were previously described.20 The colony was main-
tained in a specific pathogen–free facility in heterozygosity and littermates
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8 and 12weeks old were used for experiments. OVA transgenic OT-I andOT-II
micewere obtained fromCharles River Laboratories (Wilmington,Mass). The
animal procedures were approved by the Istituto Clinico Humanitas, accord-
ing to the Italian Institutional Animal Care and Use Committee and European
Union directive for animal experiments. Details about the experimental
design, in vivo procedure, and treatments are described in the supplementary
Methods in this article’s Online Repository at www.jacionline.org.ELISA tests
Quantification of mouse Ccl17 and Ccl22 and human CCL17, CCL22,
and C-X-C motif chemokine ligand (CXCL)-10 were determined with
ELISA kits (R&D Systems, Minneapolis, Minn), according to manufac-
turer’s instructions. Human LPS-binding protein was determined in the sera
of patients with OS and age-matched HDs using human LBP ELISA kit
(MyBioSource, San Diego, Calif), used according to manufacturing’s
instructions.Quantification of adherent bacteria to cutaneous
epithelium
One centimeter of skin biopsies was collected from age- and sex-matched
mice using sterile conditions and digested in lysis buffer (10 mmol/L TRIS,
100 mmol/L NaCl, 10 mmol/L EDTA, 0.5% SDS, and 0.4 mg/mL proteinase
K). Total DNA was extracted with the isopropanol-ethanol method. The
microbial load was determinedwith real-time quantitative PCR (SYBR green)
using 16S and 18S ribosomal RNA gene-specific probes.20Mouse cutaneous cell preparation
Skin tissue was digested with Liberase TL (0.45 mg/mL; Roche, Basel,
Switzerland) for 1 hour at 378C. Cell suspensionwaswashed, passed through a
100-mm cell strainer, and analyzed by flow cytometry,Lymph flow assessment using EB
Three mL of 1% Evans blue dye (EB) solution in PBS was injected into the
back of anesthetized mice using a Hamilton syringe (Hamilton Company,
Reno, Nev). After 16 hours mice were sacrificed. EB was extracted from the
skin biopsies of the back by incubating them at 558C for 5.5 hours in
formamide (Honeywell Fluka, Thermo Fisher Scientific, Waltham, Mass).
The absorbance was measured with microplate reader at 620 nm. The dye
concentration was calculated from a standard curve of EB in formamide
(Sigma-Aldrich, St Louis, Mo) and is represented as absolute amount of dye
remaining in the skin tissue.Flow cytometry
Cell suspensions obtained from mouse organs were preincubated with
FcgR-specific blocking antibodies (eBioscience, San Diego, Calif) and
stained with the following antibodies from eBioscience: TCR-gd (UC7-
13D5), CD45 (30-F11), CD4 (RM4-5), CD8a (53-6.7), CCR9 (CW-1.2),
CD103 (2E7), CD11C (N418), MHCII (M5/114.15.2), CCR4 (2G12), IL-
17A (17B7) and IFN-g (XMG1.2). Dead cells exclusion was performed
with Aqua Cell Stain kit (Invitrogen, Thermo Fisher Scientific). For
intracellular staining, cells were stimulated for 4 hours with phorbol 12-
myristate 13-acetate (5 ng/ml; Sigma-Aldrich) and ionomycin (1 mg/ml;
Sigma-Aldrich). Golgi stop (10003; BD, Franklin Lakes, NJ) was added
during the last 3 hours of stimulation. Cell fixation and permeabilization
was performed using the Fixation and Permeabilization Buffer kit
(eBioscience). Human cells were stained with the following antibodies
from BioLegend (San Diego, Calif): CD4 (OKT4), CD8 (RPA-T8),
CD45RA (HI100), CD45RO (UCHL1), CLA (HECA-452), CCR4
(L291H4). Fluorescence-activated cell sorting (FACS) data were acquiredwith FACSCanto II (BD) and analyzed with FlowJo software (version
9.9.6; Tree Star, BD).Real-time PCR
Cutaneous tissues (1 cm2) were homogenized in PureZOL reagent (Bio-
Rad Laboratories, Hercules, Calif) using TissueLyzer II (QIAGEN, Hilden,
Germany). RNA was extracted using RNeasy Lipid Tissue kit (QIAGEN).
A total of 1 mg of RNA was used to synthetize cDNA using the High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
Calif). Gene expression was investigated by SYBR green RT-qPCR using
the CFX384 system (Bio-Rad). The housekeeping gene b-actin (Actb) ribo-
somal RNAwas used as control. List of primers are available in Table E2 in
this article’s Online Repository at www.jacionline.org.Histology and immunohistochemistry
Mouse tissue samples were formalin-fixed and paraffin-embedded. Sec-
tions (1.5 mm) were used for routine hematoxylin and eosin (H&E) analysis
and staining with primary antibodies. Arbitrary gut and skin histological score
was calculated in a double-blind study by a pathologist. Scoring from 0 to 3
(where 0 is normal condition and 3 is severe structural changes) was adopted
for evaluating different manifestations in each tissue. Detailed description of
histological and morphometric analyses are described in the supplementary
Methods in the Online Repository.In situ RNA hybridization
In situ hybridization for IFN-g, CXCL9, and CXCL10 on formalin-fixed
paraffin-embedded samples was performed using the RNAscope 2.5 HD
Assay-BROWN (Advanced Cell Diagnostics, Newark, Calif) according to
the manufacturer’s instructions. POLR2A mRNA labelling was used as posi-
tive control for the RNA quality in samples. Staining procedure is described in
the supplementary Methods in the Online Repository.Statistical analysis
Statistical analysis was conducted using GraphPad Prism software (Graph-
Pad Software Inc, La Jolla, Calif). Results were analyzed using the
nonparametric Mann-Whitney test or the ANOVAwith multiple comparisons
test. Data are generally shown as mean6 SEM unless otherwise stated. Value
of P < .05 was considered significant.RESULTS
Enhanced skin tropism of PB memory T cells in
patients with OS
Erythroderma, with skin infiltration by autoreactive and
oligoclonal autologous T cells, represents the clinical hallmark
of OS. CLA controls the influx of memory T cells to cutaneous
sites.21 We studied 15 patients with OS due to RAG mutations
(Table E1) and 37 healthy infants (HDs) and examined CLA
expression in PB T cells. In both CD4 and CD8 effector/memory
CD45R01 T cell subsets, the frequency of CLA1 cells was
dramatically increased in patients with OS compared with age-
matched HDs (Fig 1, A). Circulating CLA1 T cells coexpress
the chemokine receptor CCR4 and rely on T-cell chemoattractant
CCL22 and CCL17 to reach the inflamed skin.5,22 Indeed, CCR4
was expressed on almost the totality of CD41 CD45RA2 cells in
patients with OS (Fig 1, A), and higher levels of the CCR4 ligands
CCL17 and CCL22 were detected in the plasma, as compared to
HDs (Fig 1, B). These features are consistent with the TH2 pheno-
type of OS, as also indicated by elevated serum levels of IL-5 and
IL-13 (Fig 1, C). Surprisingly, we found that patients with OS
FIG 1. Preferential homing of T cells to the skin in patients with OS. A, Representative FACS plots and fre-
quencies of CLA1 CD45RO1 T cells within the effector CD41 and CD81 T-cell populations isolated from PB of
patients with OS (n5 13) and aged-matched HDs (n5 31). Frequencies of CCR41within the CD41 CD45RA2
T-cell population (n5 11-15). Plasma levels of chemokines (B) and cytokines (C) in HDs (n 5 37), in patients
with OS (n5 15) as well as in patients with acute graft-versus-host disease (GvHD) (n5 15) and patients with
AD (n5 14), as controls of TH1- and TH2-mediated inflammation, respectively. D, Skin biopsies from patients
with OS were investigated for IFNG, CXCL9, and CXCL10 mRNA expression using RNAscope. POLR2A
mRNA labeling was used as control for the quality of the RNA on paraffin section. Values are mean 6
SEM. *P < .05, **P < .01, ***P < .005, ****P < .001. Statistical significance determined by Mann-Whitney
U test or by ANOVA. See also Table E1.
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g–inducible chemokines CXCL9 and CXCL10, as well as of IL-
13, IL-5, and IL-17 (Fig 1, B and C). Furthermore, plasma levels
of TH1 and TH2 cytokines were significantly higher in patients
with OS than in patients with graft-versus-host disease and AD,
2 prototypic conditions characterized by TH1 and TH2 skewing,
respectively (Fig 1, C). Altogether, these data indicate that the
inflammation of OS is characterized by a systemic and broad
signature. Consistent with this, IFNG and to greater extent
CXCL9 and CXCL10 mRNA signals were readily detected in
skin biopsies from patients with OS (Fig 1, D and Fig E1 in this
article’s Online Repository at www.jacionline.org).Skin inflammation in Rag2R229Q mice is
characterized by T-cell infiltration and a TH1-biased
cytokine response
To investigate specifically the pathophysiology of skin dis-
ease in OS, we used the Rag2R229Q mouse model.14,23 Typically,
mutant mice develop epidermal hyperplasia, hyperkeratosis, and
dermal immune cell infiltration (Fig 2, A and B). Such alter-
ations, associated with massive signs of subcutaneous hemor-
rhage and PLN enlargement, were much more pronounced in
mice with overt skin erythroderma (Fig E2 in this article’s On-
line Repository at www.jacionline.org). Immunophenotypic
analysis of the skin infiltrate confirmed an expansion of mono-
nuclear CD451 cells, particularly of CD41 and CD81 T cells
(Fig 2, C and D). Moreover, the cutaneous expression of the
chemokine receptor Cxcr3 was increased in mutant mice (Fig
2, E). Consistent with this, CD31 T cells isolated from the
skin of Rag2R229Q mice displayed much higher frequencies of
Ifn-g–producing cells on phorbol 12-myristate 13-acetate and
ionomycin pulsing than those from wild-type (WT) control
mice (Fig 2, F). Of note, the proportion of Il-17–producing cells
in mutant mice was comparable to what observed in controls,
despite lack of Tcrgd1T cells, the main producers of this cyto-
kine in the skin (Fig 2, F and G).Rag2R229Q mice exhibit dysfunction of the
epidermal barrier and increased microbial challenge
At steady state, the epidermis ofRag2R229Qmice appears thick-
ened compared with the epidermis ofWTmice (Fig 3,A). Expres-
sion of the epidermal differentiation markers, cytokeratin 5 (Ck5)
and loricrin, was markedly increased (Fig 3, B). Similarly, the
mRNA level of the hyperproliferative/wound-associated cytoker-
atin 6 (Ck6) was also augmented (Fig 3, B), overall indicating an
altered keratinocyte differentiation program. Antimicrobial
peptides are significantly upregulated in mouse models with
altered skin barrier.24,25 We found that cutaneous expression of
cathelin-related antimicrobial peptides (Cramp) and b-defensin
3 (mb-d3) was increased in Rag2R229Q mice (Fig 3, C). Further-
more, mutant mice exhibited augmented tissue expressions of
several Toll-like receptors (Tlrs) as well as of the downstream
adaptor molecules, myeloid differentiation primary response 88
(MyD88) and TIR-domain–containing adapter-inducing IFN-b
(Trif) (Fig 3,D and E), suggestive of disturbance in the cutaneous
barrier integrity and increased microbial challenge. In line with
this, skin bacterial load was increased in Rag2R229Q mice (Fig
E3, A in this article’s Online Repository at www.jacionline.
org), indicating a possible expansion of the overall number ofbacteria compared with in their WT littermates. Notably, 16S ri-
bosomal RNA gene sequencing revealed that bacterial taxonomic
richness was generally reduced in the skin of Rag-mutant mice
(Fig E3, B), with lower abundance of Propionibacterium (Padj <
.028), Bacteroides (Padj < .009), and Staphylococcus (Padj <
.008) (Fig E3, C) genera, which are cutaneous commensal bacte-
ria contributing to maintenance of tissue homeostasis.26
Following the observation that cutaneous Toll-like receptor 4
(Tlr4) expression was markedly upregulated in Rag2R229Q mice,
we examined further the effect of local Tlr4 activation. Mice
received a single intradermal injection of 100-mg LPS on the right
portion of the back and of PBS on the left and were sacrificed 24
hours later. Hemorrhage and dermal tissue necrosis were evident
at the LPS injection site in almost all treated mutant mice (Fig 3,
F). In particular, histopathology of skin sections revealed wide-
spread epidermal thickening with hyperkeratosis and increased
abscess formation and hemorrhage. By contrast, WT mice
showed mild signs of hemorrhage and no microabscesses (Fig
3, F). We also analyzed the expression of the CK6-inducing cyto-
kine Il-1b27 as well as of Ifng, involved in the pathogenesis of in-
flammatory skin diseases.28 Expression of both cytokines was
strongly induced in the skin of Rag2R229Q mice in response to
LPS (Fig 3, G). Moreover, the augmented expression of the
keratinocyte-derived Cxcl2 chemokine correlated with a robust
recruitment of innate cells to the skin of Rag2R229Q mice (Fig 3,
G). Thus, Rag2R229Q mice are more susceptible to LPS-induced
cutaneous inflammation.Chronic skin inflammation sustains immune cell
infiltration in Rag2R229Q mice
Chronic microbial stimulation may induce keratinocyte acti-
vation.29-31 Skin epithelial cells of Rag2R229Q mice expressed
high levels of MHC class II molecules (Fig 4, A). Moreover, the
expression of several cytokines, including Ifn-g, Tnf-a, Il-23,
Il-1b, Il-5, Il-13, Il-33, and thymic stromal lymphopoietin
(Tslp), was significantly upregulated in the mutant skin (Fig 4,
B), suggesting that these cytokines may contribute to skin inflam-
mation, without an obvious skewing of TH responses. Consistent
with this, levels of both TH1 (Cxcl9, Cxcl10) and TH2 (Ccl20,
Ccl22, and Ccl17)-related chemokine transcripts were markedly
increased in the skin of Rag2R229Q mice (Fig 4, C). Levels of
Ccl17 and Ccl22 were also elevated in the serum of RagR229Q
mice (Fig 4, D), correlating with a higher frequency of Ccr4-
expressing skin homing CD31 T cells detected in the PLNs,
spleen, and MLNs (Fig 4, E). Overall, these data mirror what is
observed in patients with OS (Fig 1) and suggest a broad inflam-
matory signature in this disease.
To test whether this inflammatory environment has a role in
promoting antigen-driven cutaneous T-cell migration, we adop-
tively transferred CD41 or CD81 lymphocytes fromOT-II or OT-
Imice intoRag2R229Q andRag21/1 recipients. Then, we topically
immunized the ear pinna once with ovalbumin (OVA) plus
cholera toxin, and after 7 days, treated mice were sacrificed. Epi-
cutaneous challenge caused marked epidermal changes in
Rag2R229Q mice, with enhanced vascularization and dermal infil-
tration by immune cells (Fig E4, A-C in this article’s Online Re-
pository at www.jacionline.org). Accumulation of transgenic T
cells was significantly increased within the cervical LNs (Fig
E4,D and E) and skin (Fig E4, F andG) of immunized Rag2R229Q
mice compared with that of controls. Overall, these findings
FIG 2. Rag2R229Q mice exhibit severe T-cell–mediated inflammation in the skin. A, Representative skin sec-
tions from Rag21/1 and Rag2R229Q mice (8-12 weeks old) stained with H&E and CD3 immunostaining. Histo-
gram shows the inflammation score in the skin (n5 12-13). Bars5 200 mm (H&E) and 100 mm (CD3). B, Total
cell count from skin suspension for g tissue (n 5 7-8 mice/group). C, Frequencies of CD451 cells in the skin
suspension (n 5 9-10 mice/group). D, Representative FACS plots and cumulative frequencies of CD41 and
CD81 T cells inside the CD451 population of skin suspension (n5 6-12 mice/group). E,Gene expression anal-
ysis of Cxcr3 in the skin tissue of Rag21/1 and Rag2R229Q mice (n 5 6-9 mice/group). Target mRNA was
normalized to Actb mRNA. RNA contents are shown as arbitrary units (AUs). F, Representative FACS plots
and frequencies of TH1, TH17, and TH2 cells inside the CD3
1 T-cell population of skin suspension (n 5 6-9
mice/group). G, Representative FACS plots showing TCRgd T cells inside the CD451 population in the skin
of Rag21/1 and Rag2R229Q mice. Values are mean 6 SEM. *P < .05; **P < .01; ***P < .005; ****P < .001. Sta-
tistical analysis was performed using Mann-Whitney U test. See also Fig E1.
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FIG 3. Altered barrier integrity and microbial load characterized the skin of Rag2R229Q mice. A, Representa-
tive skin sections from Rag21/1 and Rag2R229Q mice stained with H&E. Bar 5 100 mm. B, Cutaneous gene
expression analysis of keratins (Ck5-Ck6) and Loricrin in Rag21/1 and Rag2R229Q mice (n 5 8-11 mice/group
from 3 experiments). Target mRNA was normalized to Actb mRNA. RNA contents are shown as AUs. C,
Gene expression analysis of Mb-d3 and Cramp in the skin tissue (n 5 4-8 mice/group). Gene expression
analysis of Tlrs (D) and Myd88 and Trif (E) in the skin tissue of Rag21/1 and Rag2R229Q mice (n 5 6-9
mice/group). Target mRNA was normalized to Actb mRNA. RNA contents are shown as AUs. F, Rag21/1
and Rag2R229Q mice received a single intradermal injection of 100 mg LPS on the left and PBS on the right
portion of the back. Mice were then sacrificed 24 hours later. Representative skin sections from dermal
LPS-treated and untreated Rag21/1 and Rag2R229Q mice stained with H&E. Bar 5 200 mm. G, Fold increase
of Il-1b, Ifng, and macrophage inflammatory protein 2 (Mip-2, also known asCxcl2) on skin tissue. Data are
representative results of 3 independent experiments with at least 6 mice/group. Values are mean 6 SEM.
*P < .05; **P < .01; ***P < .005. Statistical analysis was performed using Mann-Whitney U test.
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FIG 4. Characterization of cutaneous inflammatory environment in Rag2R229Q mice. A, Mean fluorescence
intensity (MFI) for MHCII expression among CD452 population of skin suspension (n 5 6-7 mice/group).
Transcriptional analysis of several cytokines (B) and chemokines (C) in the skin tissue (n 5 6-9 mice/group
from 3 experiments). Target mRNA was normalized to Actb mRNA. RNA contents are shown as AUs. D,
Levels of the chemokines Ccl17 and Ccl22 in the serum of Rag21/1 and Rag2R229Q mice (n 5 12-13 mice/
group from 3 experiments). E, Representative FACS plots and cumulative frequencies of CCR41 inside
the CD31 T-cell population of spleen, MLN, and DLN (n 5 14 mice/group from 3 experiments). Values are
mean 6 SEM. *P < .05; **P < .01; ***P < .005; ****P < .001. Statistical analysis was performed using
Mann-Whitney U test. See also Fig E3. SSC-A, Side scatter.
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FIG 5. Increased DC trafficking from the skin of Rag2R229Qmice. A, Gene expression analysis of Vegfa in the
skin tissue of Rag21/1 and Rag2R229Q mice (n 5 6-9 mice/group from 3 experiments). B, Representative skin
sections stained with CD31. Bar 5 100 mm. The evaluation of several parameters was performed by
computer-assisted morphometric analysis of CD31-stained skin sections (n 5 5 mice/group). C, Quantifica-
tion of extracted EB from the back skin of Rag21/1 and Rag2R229Qmice, normalized to tissue weight (g). Data
are representative results of 3 independent experiments with at least 4 mice per group. D, Allophycocyanin-
labeled OVA antigen was intradermally injected in the ears of Rag21/1 and Rag2R229Qmice, and its uptake by
DCs was evaluated in the skin and DLNs after 6 hours. Representative dot plots and frequencies of OVA-
loaded DCs from skin (CD11c1 MHCII1) and DLNs (CD11c1) of OVA-injected Rag21/1 and Rag2R229Q and
negative control (not injected). Data are representative results of 3 independent experiments with at least
5 mice per group. Values are mean 6 SEM. *P < .05; **P < .01; ***P < .005. Statistical analysis was per-
formed using unpaired Student’s t test and Mann-Whitney U test. CTL, Control.
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FIG 6. Systemic LPS triggers cutaneous inflammation. A, LPS-binding protein (LBP) concentration in the
sera of patients with OS and HDs (n 5 8-9 from 2 experiments). B, Rag21/1 and Rag2R229Q mice received
a single injection of 100 mg LPS intraperitoneally and were sacrificed 24 hours later. Representative skin sec-
tions from systemic LPS-treated and untreated Rag21/1 and Rag2R229Q mice stained with H&E. Bar 5 200
mm. C, Histogram shows the inflammation score in the skin of n 5 6-11 mice/group from 2 experiments.
D, Fold increase of Ifng and Tlr4 on skin tissue (n 5 6-8 mice/group from 2 experiments). E, Representative
small intestinal and skin sections from Rag2R229Qmice with erythroderma stained with H&E and CD3 immu-
nostaining. Bar5 200 mm. F, Correlation between intestinal and skin inflammation scores of Rag2R229Qmice
manifesting or not evident cutaneous manifestations (black dots). The Spearman r value is indicated in the
graph (n 5 10 mice). Values are mean 6 SEM. **P < .01. Statistical analysis was performed using Mann-
Whitney U test.
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FIG 7. Boosted intestinal inflammation worsens skin inflammation in Rag2R229Q mice. A, Colitis in
Rag2R229Q mice was induced by cyclic DSS administration. Representative skin sections stained with H&E
and CD3 immunostaining. Bars 5 200 mm (H&E) and 100 mm (CD3). Higher magnification shows eosino-
phils. Bar 5 50 mm. Histogram shows the inflammation score in the skin (n 5 12-15 mice/group from 3 ex-
periments). B, Representative skin sections from untreated and DSS-treated Rag2R229Qmice stained with
CD31 immunostaining (asterisksmark the CD31-positive vessels). Bar 5 100 mm. Correlation between cuta-
neous inflammation and average vessels size of untreated Rag2R229Q (black dots) and DSS-treated
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environment in mutant mice contribute to T-cell skin homing and
infiltration.
Enhanced peripheral trafficking of skin-derived DCs
in Rag2R229Q mice
Cell trafficking to inflamed tissues is influenced by vascular
remodeling.32 We found that levels of the angiogenic vascular
endothelial growth factor A (Vegfa) were elevated, and CD311
endothelial cells were present at higher number and density in
the skin of Rag2R229Q mice (Fig 5, A and B). To investigate
possible abnormalities of lymphatic vessels, we quantified the up-
take and drainage of the lymphatic tracking dye EB after intrader-
mal injection into the back skin.33 Significantly less EB remained
localized within the skin of Rag2R229Q compared with in WT
mice, indicating enhanced lymphatic clearance (Fig 5,C). Hence,
trafficking of antigens and immune cells from the skin of
Rag2R229Q mice could be facilitated by the expanded lymphatic
network. To test this hypothesis, allophycocyanin-labeled OVA
antigen was intradermally injected in the ear pinna of mice, and
its uptake and transport by DCs was evaluated in the skin and
draining lymph nodes (DLNs) after 6 hours. Comparable fre-
quencies of OVA-loaded DCs were detected locally within the
skin tissue of Rag2R229Q and Rag21/1mice (Fig 5, D). However,
consistent with the enhanced EB dye transport, a higher propor-
tion of OVA-positive DCs was recovered in the DLNs of
Rag2R229Q mice compared with in controls (Fig 5, D).
Skin disease in Rag2R229Q mice is exacerbated by
intestinal inflammation
The aforementioned results indicate that endogenous Tlr4
ligands could have a role in cutaneous inflammation of Rag2R229Q
mice. We previously reported high levels of endotoxin (LPS) in
the circulation of Rag2R229Q mice correlating with gut dysbiosis
and intestinal inflammation.20 Increased levels of LPS-binding
protein, marker ofmicrobial load and translocation, were detected
also in sera of patients with OS (Fig 6, A), with the highest levels
found in patients exhibiting intestinal inflammation and profuse
diarrhea. To evaluate whether high serum endotoxin may
contribute to skin inflammation in Rag2R229Q mice, we analyzed
the cutaneous responses to systemic LPS. Mice received a single
injection of 100 mg LPS intraperitoneally and were sacrificed 24
hours later. Histological examination of skin biopsies showed
worsening of inflammation over baseline condition in Rag2R229Q
mice, with increased epidermal thickening, hyperkeratosis, occa-
sional abscesses, and more prominent dermal infiltrates (Fig 6, B
and C). Signs of inflammation were evident also in the skin of
LPS-treated Rag21/1mice, similar to those observed in untreated
Rag2R229Qmice (Fig 6,C). Furthermore, on LPS challenge, levels
of Tlr4 and Ifng transcripts were significantly upregulated in
Rag2R229Q mice and, to a lesser extent, in Rag21/1 mice (Fig 6,Rag2R229Q (blue dots). The Spearman r value is indicate
the CD41 and CD81 T-cell frequencies (n5 6-9mice/gro
Ccl20, Tslp, and Tlr4 expressions (n 5 6-9 mice/group).
tion of Rag2R229Q and DSS-treated Rag2R229Q skin suspe
plots and cumulative frequencies of splenic Ccr41, Ccr91
from 3 experiments). Dotted line indicates WT averages
.005. Statistical significance determined by Mann-Whit
=D), indicating that systemic endotoxin can play a role in the cuta-
neous inflammation ofRag2R229Qmice. Skin homeostasis was not
markedly altered in mutant mice at weaning, likely reflecting the
reduced LBP levels compared with LBP levels in adult mice and
the time of exposure to endotoxin (Fig E5 in this article’s Online
Repository at www.jacionline.org).
Moreover, we observed that Rag2R229Q mice in which the skin
inflammation was more pronounced were those in which intesti-
nal disease was also more severe (Fig 6, E and F). To determine
the potential role of the gut-skin axis in the disease pathophysi-
ology, we boosted intestinal inflammation in Rag2R229Q mice us-
ing chronic dextran sulfate sodium salt (DSS) treatment. Mice
were sacrificed after 4 weeks. DSS-treated Rag2R229Q mice man-
ifested worsened skin inflammation, as indicated by enhanced
epidermal thickening, hyperkeratosis, and increased number of
CD31 T cells infiltrating the dermis (Fig 7, A). Furthermore, im-
munostaining for CD31 demonstrated enhanced cutaneous vascu-
larization in DSS-treated Rag2R229Qmice (Fig 7, B). By contrast,
DSS treatment did not induce similar skin abnormalities in
Rag21/1mice (Fig E6, A and B in this article’s Online Repository
at www.jacionline.org). FACS analysis of cutaneous cell suspen-
sions confirmed that the proportion of skin-infiltrating CD41 T
cells and CD81 T cells was increased by 2- to 4-fold in DSS-
treated Rag2R229Q mice (Fig 7, C). Moreover, the frequency of
circulating CD41 Ccr41 T cells was significantly increased in
DSS-Rag2R229Qmice (Fig 7, F), with a significant proportion co-
expressing also the gut-homing receptor Ccr9 (Fig 7, F), thus sug-
gesting that memory T cells in Rag2R229Q mice may recirculate
between skin and intestinal mucosa. Cutaneous levels of Cxcr3
and Ifng transcripts were upregulated in DSS-Rag2R229Q mice
(Fig 7, D), leading to enhanced epithelial expression of MHC-II
molecules and keratinocyte hyperactivation (Fig 7, E).34
Finally, we investigated whether the mechanism for endotoxin-
driven skin disease exacerbation is applicable to mice not
displaying preexisting inflammatory bowel disease. To this end,
we tested the effect of acute DSS in a mouse model of AD.
Experimental AD was induced by daily topical application of the
vitamin D3 analog MC903 on the ears. At day 8, groups of mice
received for 7 days water with or without 2% DSS, followed by
normal drinking water for an additional 2 days, and then
euthanized. Plasma LBP was significantly augmented in mice
receiving DSS administration (Fig E7, A in this article’s Online
Repository at www.jacionline.org), which caused increased
swelling, reddening, and scaling of the skin in the treated mice
(Fig E7, B and C). Microscopic investigation revealed a stronger
dermal inflammatory cell infiltration with epidermal hyperplasia
and hyperkeratosis in DSS-treated AD mice (Fig E7, D). Consis-
tent with increased inflammation, the expression of TH1 and TH2
inflammatory markers was augmented (Fig E7, E).
Collectively, these results suggest that a leaky gut plays an
important role in priming the skin disease for a hyperinflamma-
tory response to systemic LPS.d in the graph (n5 5 mice/group). C, Fold change of
up). D, Fold change of cutaneous Cxcr3, Cxcl10, Ifng,
E,MFI for MHCII expression among CD452 popula-
nsion (n5 5-6 mice/group). F, Representative FACS
, and Ccr41Ccr91CD41 T cells (n5 6-11mice/group
. Values are mean6 SEM. *P < .05; **P < .01; ***P <
ney U test. See also Fig E4.
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The cutaneous hallmark of OS is a severe exfoliative eryth-
roderma, resulting in epidermal barrier defect and subsequent risk
of life-threatening bacterial infections. The aberrant expression of
skin-homing molecules CLA and CCR4 on T cells from patients
with OS, together with the high CCL17/CCL22 serum levels,
indicates that they are poised to migrate to the inflamed skin and
have pathogenic potential.35 Along with high serum levels of IL-
13 and IL-5, these observations may also sustain the notion that
OS is a TH2-driven disease. Surprisingly, we detected high levels
also of IFN-g, CXCL9, and CXCL10 in the serum of patients with
OS. Similar results have been demonstrated both in the skin and in
circulation of Rag2R229Q mice, indicating that OS is not a pure
TH2-driven disease, but rather manifests a broad inflammatory
signature, with a prominent role also for TH1-mediated responses.
Many studies reported promiscuous expression of chemokines in
the serum of patients with cutaneous inflammation,36 proposing
that the immunological phenotype in T-cell–mediated skin dis-
eases can shift toward a TH2/TH1/TH17 mixed response as the
duration of the disease increases.37 Furthermore, although expres-
sion of CCR4 is more commonly associated with TH2 responses, it
has also been observed on TH17 cells, suggesting that the chemo-
kines activating this receptor may have a broader impact on the
inflammatory response than simply recruiting TH2 cells.
38 Indeed,
CCR41 memory T cells also contain non-TH2 populations ex-
pressing CXCR3 and IFN-g39 and CCL17 and CCL22 can be
released not only by leukocytes, but also by activated dermal
endothelial cells and keratinocytes, in response to both TH1 and
TH2 cytokines.
34 Both CCR4 and CXCR3 antagonists are avail-
able for the treatment of allergic disease and psoriasis40,41 and
may represent a novel therapeutic target also in OS.
Increased expression of Tlr4 and downstream signaling mole-
cules Myd88 and Trif in the skin of Rag2R229Q mice correlated
with hyperinflammatory cutaneous responses on topical or sys-
temic administration of LPS. Together with our previous demon-
stration of inflammatory bowel disease–like disease, altered gut
microbiota, and elevated LPS serum levels in Rag2R229Q
mice,20 these findings suggest that endogenous Tlr4 ligands
play a role in the maintenance of keratinocyte activation and
perpetuation of local inflammatory response.42 Consistently,
DSS treatment markedly worsened cutaneous inflammation in
Rag2R229Q mice. Chronic gastrointestinal diseases, such as in-
flammatory bowel disease or celiac disease, are often associated
with skin inflammation.43,44 Likewise, marked changes in gut
barrier and in intestinal microbiota are observed in AD and pa-
tients with rosacea.45 However, it cannot be excluded that inflam-
mation in other organsmay also contribute to increase the severity
of skin inflammation in OS.46
High cutaneous expression of antimicrobial peptides and Tlrs
in the Rag2R229Q mice is indicative of important alterations of
skin barrier integrity and microbial challenge. Changes of the
cutaneous microbiota have been correlated with several skin dis-
orders.47-49 Here we have shown that Rag2R229Qmice manifested
a selective shift in resident skin microbiota with decreased abun-
dance of commensal bacteria belonging to Actinobacteria and
Firmicutes phyla. The loss of some protective bacteria genera
(Streptococcus, Staphylococcus, and Propionibacterium) might
render the skin of Rag2R229Q mice more susceptible to develop-
ment of local inflammation. These data indicate the importance
of performing similar studies also in patients with OS, althoughthe frequent use of immunosuppressive agents and antibiotics in
these patients may affect interpretation of the results.
Similar to patients with OS, an increased proportion of Ccr4-
expressing CD41 T cells was detectable in lymphoid organs of
Rag2R229Q mice, indicating that these cells are poised to migrate
to the skin. Interestingly, we observed coexpression of skin-
homing (Ccr4) and gut-homing (Ccr9) expression by a subset of
splenic T cells in DSS-treated Rag2R229Q mice, suggesting that
these cells might be potentially able to recirculate between gut
and skin. Plasticity in the migratory property of immune cells
has been suggested. Particularly, cutaneous exposure to food an-
tigens can reprogram LN effector T cells expressing gut-homing
receptors to express skin-homing receptors, thereby eliciting skin
inflammation.50 Tissue-derived DCs have a key role in presenting
local antigens and imprinting T cells with specific homing prop-
erties. Trafficking of skin-derived DCs to DLNs is increased in
Rag2R229Q mice, correlating with abundant lymphatic network.
Moreover, we previously described an augmented population of
migratory CD1031 DCs in the spleen of Rag2R229Q mice,51 sug-
gesting that reprogramming of T cell homing by tissue-derived
DCs may also occur in secondary lymphoid organs other than
DLNs. Intriguingly, skin-derived and antigen-bearing DCs were
also identified in MLNs.50 Hence, breaches of skin and gut bar-
riers in Rag2R229Q mice may promote systemic translocation of
microbial antigens and induce activation of T cells expressing
homing receptors for skin and/or gut. In summary, we have
demonstrated that the cutaneous manifestations of OS are charac-
terized by a broad inflammatory signature and can be severely
influenced by gut inflammation, reinforcing the notion of an inter-
play between skin and gut in the pathophysiology of the disease.
Key messages
d A broad TH1/TH2/TH17 inflammatory signature is
observed in the blood and skin of patients with OS and
in the murine model.
d Systemic LPS injection or boosting colitis in OS murine
model aggravates cutaneous T-cell infiltration and skin
inflammation.
d High level of serum endotoxin is detected in patients with
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METHODS
Histology and immunohistochemistry
Mouse tissue samples were formalin-fixed and paraffin-embedded. Sec-
tions (1.5 mm) were used for routine H&E staining. Moreover, sections were
dewaxed and rehydrated; endogenous peroxidase activity was blocked by
0.1%H2O2; nonspecific backgroundwas reduced with Rodent Block (Biocare
Medical, Pacheco, Calif) before microwaves or thermostatic bath treatment;
and incubated with primary antibodies. The following primary antibodies
were used: rabbit anti-CD3 (1:100; EDTA buffer pH 8.0; 1 hour at room tem-
perature [RT]; Thermo Fisher Scientific), rabbit anti-Ki67 (1:350; citrate
buffer pH 6.0; 1 hour RT; Cell Signaling Technology, Danvers, Mass), rabbit
anti-keratin 5 (1:200; EDTAbuffer pH 8.0; 1 hour RT; BioLegend), rabbit anti-
myeloperoxidase (1:300; EDTAbuffer pH 8.0; overnight; Abcam,Cambridge,
Mass), and goat anti-CD31 (1:1000; R&D Systems; DIVA Decloaker 13;
Biocare Medical). Depending on the primary antibodies and tissue used, sec-
tions were incubated with Goat-on-Mouse HRP-Polymer (Biocare Medical),
MACH 1 Universal HRP Polymer Kit (Biocare Medical); reactions were
developed in Biocare’s Betazoid DAB; and nuclei were counterstained with
Hematoxylin (Dako, Agilent, Santa Clara, Calif). Digital images were ac-
quired by an Olympus XC50 camera mounted on a BX51 microscope
(Olympus, Tokyo, Japan) or by an Olympus DP70 camera mounted on a
BX60 microscope (Olympus), with CellF Imaging software (Soft Imaging
System GmbH, M€unster, Germany).
Histological score. Arbitrary gut and skin histological score was
calculated in a double-blind study by a pathologist. Scoring from 0 to 3 (where
0 is normal condition and 3 is severe structural changes) was adopted for
evaluating differentmanifestations in each tissue. For gut analysis, a combined
score—grade of inflammation, the structural changes of the glands, and the
goblet cell depletion—was used. For skin analysis, abnormalities of
keratinocytes, increased immune cells in the dermis, alterations of the
epidermis, and presence of cutaneous abscesses were evaluated. Specifically,
for DSS treatment, the number of CD31 aggregates was also analyzed.
Morphometric analysis. Histological dermal thickness was
determined, on H&E-stained sections, by measuring the distance between
the epidermal-dermal junction and dermal–subcutaneous fat junction (60
fields for each sample). Morphometric analysis to evaluate coverage, number
of vessels, and size was determined on CD31-stained sections. Both analyses
were performed using Olympus Slide Scanner VS120-L100 to acquire digital
images and Image-Pro software (Media Cybernetics, Rockville, Md).
Mice and in vivo treatments
OT-I and OT-II adoptive transfer. Splenic CD81 OT-I cells or
CD41 OT-II cells were sorted from donor mice. T cells (33 106) were adop-
tively transferred intravenously into Rag21/1 and Rag2R229Q mice (CD45.1).
The day after, ears were immunized.E1 Briefly, both sides of each ear were
gently stripped 10 times with Scotch Tape (3M, St Paul, Minn) and 25 mL
of acetone was applied and evaporated. Then, 20 mL of cholera toxin (CT)
or CT1 50mL of OVA (100mg/mL; Sigma-Aldrich) was applied with a small
paintbrush on the ears of recipient mice. Rag21/1 and Rag2R229Q mice were
sacrificed after 7 days from topical immunization.
Coculture DC-T cells. Topical immunizationof ear skin ofRag21/1
and Rag2R229Q mice was performed as described above. Briefly, CT plus OVA
orCTalonewas applied directly on ear skin. After 4 days,DCs from spleen and
DLNs were sorted from OVA-immunized Rag21/1 and Rag2R229Q mice and
CT controls. DCs were put in coculture with CD41 OT-II cells in 96-well
round-bottom plates. A 1:1 DC–T cell ratio was used for the assay. Cocultures
weremaintained for 6 days and T-cell proliferationwas evaluated by overnight
incorporation of (3H)-thymidine.
In vivo treatments. Acute DSS treatment was induced by adding
2.5% of DSS (MPBiomedicals, Santa Ana, Calif) to drinking water ad libitum
for 6 days. Treated and untreated mice were sacrificed at day 7, and
transcriptional analyses were performed on skin tissue. Chronic colitis was
induced by adding 1.5% of DSS to drinking water ad libitum for 4 cycles
for a total of 4 weeks. Control mice received water continuously throughout
all the experiment. For topical and systemic LPS administration, mice were
anesthetized and injected intradermally into the back with 100 mg of LPS
(right side) and PBS (left side) using Hamilton syringes. After 24 hours,
LPS-treated micewere sacrificed and skin tissues were processed for histolog-
ical analysis and quantitative RT-PCR analysis. For systemic LPS administra-
tion, mice were injected intraperitoneally with 100 mg of LPS. Systemic
LPS-treatedmicewere sacrificed 24 hours later. Skin tissues were used for his-
tological scores and transcriptional analysis. Micewere injected intradermally
into the ear’s skin with 100 mg/mL OVA–Alexa Fluor (Thermo Fisher Scien-
tific) with Hamilton syringe. After 6 hours, DLNs and ear tissues were
collected. The analysis of OVA-loaded CD11C1 DCs from ears and DLNs
was performed by FACS.
In situ RNA hybridization. Slides were deparaffinized in xylene
(23, 5minutes each) and 100%ethyl alcohol (23, 1minute each) and air dried
at RT, followed by H2O2 (Cat no 322330; ACDBio, Advanced Cell Diagnos-
tics) at RT for 10 minutes. Slides were submerged in 700 mL fresh 1X Target
Retrieval (Cat no 322000; ACDBio) at boiling for 15minutes and immediately
washed in deionized water followed by 100% ethyl alcohol and air dried.
A hydrophobic barrier was drawn around tissue and protease plus (Cat no
322330; ACDBio) was applied for 15 minutes in a HybEZ oven (Cat no
322310; ACDBio) at 408C. Slides were washed in deionized water and probes
were added for 2 hours in the HybEZ oven. Signal amplification reagents
antimicrobial peptide (AMP) 1 (30 minutes), AMP 2 (15 minutes), AMP 3
(30 minutes), AMP 4 (15 minutes), AMP 5 (75 minutes), and AMP 6 (15
minutes) were applied sequentially and incubated in the HybEZ oven. Before
adding each AMP reagent, samples were washed twice with washing buffer
(Cat no 310091; ACDBio). Diaminobenzidine chromogen detection reagent
was applied and incubated for 10 minutes in the HybEZ oven. Samples were
then counterstained, rinsedwith tapwater, and placed in 0.02%ammoniawater
followed by another tap water rinse. Samples were then dehydrated in graded
alcohols followed by xylene treatment (23, 5 minutes each) and cover slipped.
Cutaneous microbiota analysis. Weaned Rag21/1 and
Rag2R229Q littermates were maintained in the separated cages until analysis.
Cutaneous tissues were weighed and digested in lysis buffer (10 mmol/L
TRIS, 100 mmol/L NaCl, 10 mmol/L EDTA, 0.5% SDS, and 0.4 mg/mL pro-
teinase K). Total DNA was extracted with the isopropanol-ethanol method.
Bacterial DNA was analyzed by real-time PCR using specific primers for
16s ribosomal RNA (rRNA) gene.Microbiota taxonomic profiling was carried
out at GenProbio Srl (Parma, Italy). In brief, primer pairs Probio Uni and Pro-
bio_RevE2 (GenProbio Srl) were used for the amplification of the region 16S
rRNA gene encompassing the V3 variable region; amplicons were then pro-
cessed and sequenced using an Illumina MiSeq sequencer (Illumina Inc,
San Diego, Calif) with MiSeq Reagent Kit chemicals (Illumina). For taxo-
nomic classification of taxonomic units, the resulting fastq files were then pro-
cessed with the bioinformatic pipeline Quantitative Insights Into Microbial
Ecology ([QIIME], version 1.7.0)E3 with the 16S rRNA gene database SILVA
(version 128E4). To identify specific bacterial taxa distinguishing the skin mi-
crobiota of Rag21/1 from Rag2R229Q mice, we used the linear discriminant
analysis effect size method.E5 Specifically, linear discriminant analysis effect
size analysis included Kruskal-Wallis and pairwise Wilcoxon tests consid-
ering significant a corrected P value of <.05.E5
Experimental model of AD
The induction of MC903 dermatitis was performed as previously described
(6). Briefly, MC903 was applied to both ears from days 0 to 8, select cages
were placed on 2% DSS water on days 8 to 15, and then all cages returned to
normal drinking water for days 16 and 17. Ear thickness was measured as
described on days 0, 8, and 17. On day 17, mice were euthanized, and ears and
serum were harvested for further analysis.
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FIG E1. Elevated CXCL9 expression in skin biopsies from patients with OS. Skin biopsies from 2 patients
with OS were analyzed for CXCL9 mRNA expression using RNAscope. POLR2AmRNA labeling was used as
control for the quality of the RNA on paraffin section.
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FIG E2. A small proportion of Rag2R229Q mice exhibits erythroderma-like phenotype. A, Cutaneous pheno-
type of Rag2R229Qmice affected by erythroderma. B,Macroscopic appearance of dorsal skin and lymph no-
des of Rag2R229Q and Rag2R229Q with erythroderma-like phenotype. C, Representative skin sections from
Rag2R229Q with evident skin erythroderma-like phenotype stained with H&E, KI67 (upper right; bar 5 500
mm), CD3 (bottom left), and myeloperoxidase (bottom right; bar5 100 mm) immunostaining. Higher magni-
fication shows eosinophils. D, Histogram shows the inflammation score of the skin (n 5 5-6 mice/group).
Values are mean 6 SEM. **P < .01. Statistical analysis was performed using Mann-Whitney U test.
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FIG E3. The composition of skin microbiota differs between Rag21/1 and Rag2R229Qmice. Skin tissuemicro-
biota from adults Rag21/1 (n5 10) and Rag2R229Q (n5 10) littermates was analyzed through 16s rRNA gene
profiling. A, Quantitative PCR analysis of cutaneous adherent bacteria in Rag21/1 and Rag2R229Q mice ex-
pressed as prokaryotic/eukaryotic DNA (ie, 16S/18S rRNA genes) ratios (n 5 12 mice/group from 3 experi-
ments). B, Scatter dot plot depicts the intrasample (a) diversity (Chao1 index) describing taxonomic
richness of skin microbiota in Rag21/1 and Rag2R229Qmice. C, A linear discriminant analysis effect size iden-
tifies the significant different abundance of bacterial taxa between Rag2R229Q mice and controls. The taxa
with significantly different abundances among the genotypes are represented by colored shadows in the
cladogram of the top panel and listed in the table below. From the center of the cladogram outward,
kingdom, phylum, class, order, family, and genus levels are shown. Heat maps represent the relative abun-
dance of significantly different taxa per sample (black-red heat map). Statistical analysis of data (A, C) was
performed using Mann-Whitney U test. *P < .05.
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FIG E4. Cutaneous inflammatory environment in mutant mice promote T-cell infiltration. A, Representative
skin section from controls and CT1OVA-treatedRag21/1 andRag2R229Qmice stainedwith H&E and CD31 im-
munostaining (asterisksmark the CD31-positive vessels). Bar 5 200 mm. B, Total skin counts from skin sus-
pension (n 5 5-12). C, Representative FACS plot and frequencies of CD451 cell population of skin
suspension (n5 5-12). D and E, CD4 or CD8 splenocytes fromOT-II or OT-I mice were adoptively transferred
into Rag21/1 and Rag2R229Q recipients. Topical immunization was applied on ears once with OVA plus CT or
only CT. Recipient mice were sacrificed after 7 days. Representative dot plots of donor-derived OT-II or OT-I
cells within total live population of DLN suspension. F and G, Representative dot plots and frequencies of
donor-derived OT-II or OT-I cells within total live population of skin suspension (n5 5-7mice/group). Values
are mean 6 SEM. **P < .01; ***P < .001. Statistical analysis was performed using Mann-Whitney U test.
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FIG E5. Analysis of skin homeostasis in young Rag2R229Qmice.A, Representative skin section from 20-days-
old Rag21/1 and Rag2R229Q mice stained with H&E. Bar 5 200 mm. B, Cumulative frequencies of CD451,
CD41, and CD81 T cells infiltrating the skin. C, Gene expression analysis of Ifng and Cxcl10 in the skin tissue
of Rag21/1 and Rag2R229Q mice (n 5 6-9 mice/group). Target mRNA was normalized to Actb mRNA. RNA
contents are shown as AUs. Plasma levels of (D) CCL17 and CCL22 and (E) LPS-binding protein (LBP). Values
are mean 6 SEM. *P < .05; **P < .01. Statistical analysis was performed using Mann-Whitney U test.
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FIG E6. Cutaneous response to DSS treatment in Rag21/1 mice. A, Representative skin sections from un-
treated and DSS-treated Rag21/1 mice stained with CD31 immunostaining (asterisks mark the CD31-
positive vessels). Bars 5 100 mm. B, Correlation between cutaneous inflammation and average vessels
size of untreated Rag21/1 (black dots) and DSS-treated Rag21/1 (blue dots). The Spearman r value is indi-
cated in the graph (n 5 5 mice/group).
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FIG E7. Effect of DSS-induced intestinal inflammation on experimental model of AD. Mice were treated with
MC903 for 8 days to induce AD-like dermatitis. Starting on day 8, a set of mice received 2% DSS water for 7
days, and then returned to normal drinkingwater for additional 2 days.A, Plasma LBP on day 17 is shown. B,
Day 17 gross phenotype of ADmice treated or not with oral DSS. Bar graph shows the difference in ear thick-
ness between day 17 and day 8 (n5 5-10 mice/group). C, Representative ear section from AD and AD1DSS
mice stained with H&E (left; bar 5 500 mm) and CK5 immunostaining (right; bar 5 200 mm). Histogram
shows the inflammation score in the ear skin (n 5 5-10). D, Gene expression analysis of the ear tissue
(n 5 5-10 mice/group). Target mRNA was normalized to Actb mRNA. RNA contents are shown as AUs.
Values are mean 6 SEM. *P < .05. Statistical analysis was performed using Mann-Whitney U test.
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TABLE E1. Clinical features of RAG patients
ID patient Gene Mutation Erythroderma Colitis/diarrhea Autoimmunity Diagnosis
SCID-400-MX RAG2 p. [L155P; R229W] Yes Yes No OS
SCID-417-UK RAG1 p. [R410Q/M1006V; M435V/M1006V] Yes No No OS
SCID-418-UK RAG1 p.[R396C; R404Q] Yes Yes No OS
SCID-419-UK RAG1 p. [R561C; R716W] Yes Yes No OS
SCID-420-UK RAG1 p.[M435V/R897*; M1006V] Yes Infectious (rotavirus) No OS
SCID-421-UK RAG1 p.[K86Vfs*33; R559S] Yes Infectious (enterovirus) ITP, hepatitis OS
SCID-426-KW RAG1 p. [L454Q; L454Q] Yes No No OS
SCID-454-IT RAG1 p. [E147fs*27; E147fs*27] Yes Yes No OS
731-UK RAG1 p. [R829fs*2; K86Vfs*33] Yes Yes No OS
769-AF RAG1 p. [K186Sfs*15; K186Sfs*15] Yes Yes No OS
884-PA RAG1 p. [Q242R/R404Q; N766I] Yes Yes No OS
SCID-375-MX RAG2 p. [G35V; G35V] Yes Yes No OS
SCID-452-KW RAG1 p. [R394W; R394W] Yes Yes No OS
HIE-118-LB RAG1 p. [R404W; R737H] Yes No ITP, AIHA OS
AIHA, Autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic purpura; SCID, severe combined immunodeficiency.
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TABLE E2. List of primers used in this study
Primer ID 5’-3’ Sequence
Actb For CTAAGGCCAACCGTGAAAAG
Actb Rev ACCAGAGGCATACAGGGACA
IL-17A For TCCAGAAGGCCCTCAGACTA
IL-17A Rev TGAGCTTCCCAGATCACAGA
IFN-g For TCAAGTGGCATAGATGTGGAAGAA
IFN-g Rev TGGCTCTGCAGGATTTTCATG
IL-5 For ATCCAGGAACTGCCTCGTC
IL-5 Rev ATCCAGGAACTGCCTCGTC
IL-13 For CCTCTGACCCTTAAGGAGCTTAT
IL-13 Rev CGTTGCACAGGGGAGTCT
IL-33 For TCCTTGCTTGGCAGT
IL-33 Rev TGCTCAATGTGTCAA
TNF-a For GACGTGGAACTGGCAGAAGAG
TNF-a Rev TTGGTGGTTTGTGAGTGTGAG
IL-1b For GCCCATCCTCTGTGACTCAT
IL-1b Rev AGGCCACAGGTATTTTGTCG
CCL20 For AACTGGGTGAAAAGGGCTGT
CCL20 Rev GTCCAATTCCATCCCAAAAA
CXCL10 For GCTGCCGTCATTTTCTGC
CXCL10 Rev TCTCACTGGCCCGTCATC
CXCL9 For CTTTTCCTCTTGGGCATCAT
CXCL9 Rev GCATCGTGCATTCCTTATCA
16s For GTGSTGCAYGGYTGTCGTCA
16s Rev ACGTCRTCCMCACCTTCCTC
18s For CTCAACACGGGAAACCTCCTCAC
18s Rev CGCTCCACCAACTAAGAAGG
IL-23p19 For AGCCAGTTCTGCTTGCAAAGG
IL-23p19 Rev GGAGGTTGTGAAGTTGCTCCATG
Cramp For AAGGAGACTGTATGTGGCAAGGCA
Cramp Rev TTTCTTGAACCGAAAGGGCTGTGC
mBD-3 For GTCAGATTGGCAGTTGTGGA
mBD-3 Rev GCTAGGGAGCACTTGTTTGC
VEGF-A For CAGGGCTTCATCGTTACAG
VEGF-A Rev CATCTTCAAGCCGTCCTGT
TLR-2 For AGCATCCTCTGAGATTTGA
TLR-2 Rev GGGGCTTCACTTCTCTGCTT
TLR-3 For TCCCCCAAAGGAGTACATT
TLR-3 Rev GATACAGGGATTGCACCCA
TLR-4 For GGACTCTGATCATGGCACTG
TLR-4 Rev CTGATCCATGCATTGGTAGGT
TLR-5 For CTGGAGCCGAGTGAGGTC
TLR-5 Rev CGGCAAGCATTGTTCTCC
TLR-9 For GAGAATCCTCCATCTCCCAAC
TLR-9 Rev CCAGAGTCTCAGCCAGCAC
TSLP For CAGCTTCGTCTCCTGA
TSLP Rev AAATGTTTTGTCGGGGAGTG
CK5 For CATTCTCAGCCGTGGTACG
CK5 Rev CAGAGCTGAGGAACATGCAG
CK6 For GTCCAGGACCTTGTTCTGCT
CK6 Rev ATCCAGCGGGTCAGGACT
CCL22 For CTGATGCAGGTCCTATGGT
CCL22 Rev GGAGTAGCTTCTTCACCCAG
CCL17 Rev TGCTTCTGGGGACTTTTCTG
CCL17 For GAATGGCCCCTTTGAAGTAA
CXCR3 Rev GGCATCTAGCACTTGACGTTC
CXCR3 For GCAGCACGAGACCTGACC
Loricrin Rev CATGAGAAAGTTAAGCCCATG
Loricrin For GGTTGCAACGGAGACAACA
Involucrin Rev TTGAGAGGTCCCTGAACCAC
Involucrin For TCCTGTGAGTTTGTTTGGTC
For, Forward; Rev, reverse.
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